An investigation for investors in NASDAQ:ZSAN shares was announced over potential securities laws violations in connection certain statements about the Company’s osteoporosis drug program, ZP-PTH, and its collaboration agreement with Eli Lily and Company.
Shares of Zosano Pharma Corp declined from over $11 in March 2015 to under $2 per share in less than one year.
Investors who purchased shares of Zosano Pharma Corp (NASDAQ:ZSAN) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm concerns whether Zosano Pharma Corp and certain of its executives and directors made false statements to investors about the Company’s osteoporosis drug program, ZP-PTH, and its collaboration agreement with Eli Lily and Company
Fremont, CA based Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company that has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Zosano Pharma Corp went public in January 2015 and shares of Zosano Pharma Corp (NASDAQ:ZSAN) grew to as high as $11.67 per share in March 2015. Since then shares of Zosano Pharma Corp (NASDAQ:ZSAN) declined to as low as $1.95 per share on January 22, 2016.
On April 18, 2016, NASDAQ:ZSAN shares closed at $2.01 per share.
Those who purchased NASDAQ:ZSAN shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com